CLRB - Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy M.D. on January 19 2024 to Discuss Iopofosine I 131 Pivotal Topline Results | Benzinga
FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host a conference call with M. Yair Levy, M.D., director of hematologic malignancies research at Texas Oncology and investigator in the CLOVER WaM pivotal study of iopofosine I 131, on Friday, January 19, 2024 at 8:30 a.m. ET.
Dr. Levy will join the Cellectar management team to discuss his perspective, as a community-based hemotologist, on the positive topline results of iopofosine I 131 in patients with relapsed/refractory Waldenstrom's macroglobulinemia, announced on January 8, 2024.
Details for the call are as follows:
| Conference call & Webcast Details: |
| Date: |
| Friday, January 19 |
| Time: |
| 8:30 am Eastern Time |
| Toll Free: |
| 1-888-886-7786 |
| International: |